World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
97
Citations
33452
World Ranking
9312
National Ranking
516

Klemens Budde publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Klemens Budde sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 778 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Klemens Budde D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Klemens Budde sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 97 D-Index — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Klemens Budde is affiliated with Charité - University Medicine Berlin in Germany. Their research primarily spans the field of Medicine, with a significant focus on Transplantation, Surgery, Infectious Diseases, Public Health, Environmental and Occupational Health, and Nephrology.

The main topics of their work include:

  • Renal Transplantation Outcomes and Treatments
  • Organ Transplantation Techniques and Outcomes
  • Organ Donation and Transplantation
  • Renal Diseases and Glomerulopathies
  • Renal and Vascular Pathologies
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research

Frequent co-authors collaborating with Klemens Budde are:

  • Fabian Halleck
  • Bilgin Osmanodja
  • Eva Schrezenmeier
  • Mira Choi
  • Marcel G. Naik

They have published extensively in prominent journals, with frequent venues including:

  • Transplant International
  • Nephrology Dialysis Transplantation
  • Journal of Clinical Medicine
  • American Journal of Transplantation
  • Transplantation

Recent papers authored or co-authored by Klemens Budde include:

  • Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations, 2021, Pediatric Neurology
  • Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients, 2021, Science Immunology
  • Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients, 2021, Journal of Clinical Investigation
  • After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy, 2020, Kidney International
  • Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy, 2022, Kidney International

In addition to journal articles, Klemens Budde has contributed to book publications, including a work published by Springer Nature titled Klinische Entscheidungsfindung mit Künstlicher Intelligenz in 2023.

Best Publications

  • Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

    John J Bissler;J Christopher Kingswood;Elżbieta Radzikowska;Bernard A Zonnenberg

  • Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

    Duska Dragun;Dominik N. Müller;Jan Hinrich Bräsen;Lutz Fritsche

  • Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus.

    F. Vincenti;S. Friman;E. Scheuermann;L. Rostaing

  • Everolimus in patients with autosomal dominant polycystic kidney disease.

    Gerd Walz;Klemens Budde;Marwan Mannaa;Jens Nürnberger

  • Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy : Second Consensus Report

    Mercè Brunet;Teun Van Gelder;Anders Åsberg;Vincent Haufroid;Vincent Haufroid

  • Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.

    Klemens Budde;Thomas Becker;Wolfgang Arns;Claudia Sommerer

  • Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.

    Nils Lachmann;Paul I. Terasaki;Klemens Budde;Lutz Liefeldt

  • CC chemokine receptor 5 and renal-transplant survival

    Michael Fischereder;Bruno Luckow;Berthold Hocher;Rudolf P Wüthrich

  • Biomarkers in acute kidney injury – pathophysiological basis and clinical performance

    E. V. Schrezenmeier;E. V. Schrezenmeier;J. Barasch;K. Budde;T. Westhoff

  • First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients

    Klemens Budde;Robert L. Schmouder;Reinhard Brunkhorst;Bjorn Nashan

  • Meta-analysis identifies multiple loci associated with kidney function–related traits in east Asian populations

    Y. Okada;X. Sim;X. Sim;M. J. Go;J. Y. Wu;J. Y. Wu

  • Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial

    Teun van Gelder;Helio Tedesco Silva;Johan W. de Fijter;Klemens Budde

  • Neutrophil gelatinase‐associated lipocalin: pathophysiology and clinical applications

    Eugenia Singer;Lajos Markó;Neal Paragas;Jonathan Barasch

  • PREDICTORS OF SUCCESS IN CONVERSION FROM CALCINEURIN INHIBITOR TO SIROLIMUS IN CHRONIC ALLOGRAFT DYSFUNCTION

    F Diekmann;K Budde;F Oppenheimer;L Fritsche

  • Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study.

    Klemens Budde;John Curtis;Gregory Knoll;Lawrence Chan

  • Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.

    Lionel Rostaing;Diego Cantarovich;Georges Mourad;Klemens Budde

  • Interleukin 6 is an autocrine growth factor for mesangial cells.

    Christian Ruef;Klemens Budde;Jill Lacy;Wolfgang Northemann

  • Three‐Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients

    Štefan Vítko;Raimund Margreiter;Willem Weimar;Jacques Dantal

  • Donor‐Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation

    L. Liefeldt;S. Brakemeier;P. Glander;J. Waiser

  • Diets and enteral supplements for improving outcomes in chronic kidney disease

    Kamyar Kalantar-Zadeh;Noël J. Cano;Klemens Budde;Charles Chazot

Frequent Co-Authors

Petra Reinke
Petra Reinke Berlin-Brandenburger Centrum für Regenerative Therapien
Martin Zeier
Martin Zeier University Hospital Heidelberg
Lionel Rostaing
Lionel Rostaing Grenoble Alpes University
Dirk Kuypers
Dirk Kuypers KU Leuven
Rolf A.K. Stahl
Rolf A.K. Stahl Universität Hamburg
Teun van Gelder
Teun van Gelder Leiden University Medical Center
Allison Tong
Allison Tong University of Sydney
Jonathan C. Craig
Jonathan C. Craig Flinders University
Kai-Uwe Eckardt
Kai-Uwe Eckardt Charité - University Medicine Berlin
Josep M. Grinyó
Josep M. Grinyó University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond the traditional MD path, there are numerous flexible and affordable online degree options to consider. These programs allow students to gain specialized knowledge and advance their careers while balancing other commitments.

One popular route is health administration. Many students look for affordable online mha programs to prepare for leadership roles in hospitals, clinics, and health systems. These programs focus on management, policy, and healthcare operations.

Advanced nursing professionals may aim to enroll in cheap online dnp programs. A Doctor of Nursing Practice (DNP) helps nurses move into top-tier clinical or administrative roles and meets growing healthcare needs.

For those intrigued by pharmaceuticals, an online pharmacy degree can open doors to work as a licensed pharmacist or in pharmaceutical research. This option is ideal for students seeking both clinical and business expertise.

Finally, the demand for data-driven professionals is increasing. Earning an online mhi (Master’s in Health Information) equips graduates for roles in data analysis, informatics, and health information technology.

Best Scientists Citing Klemens Budde

Trending Scientists

Recently Published Articles